<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013674</url>
  </required_header>
  <id_info>
    <org_study_id>20120660</org_study_id>
    <nct_id>NCT02013674</nct_id>
  </id_info>
  <brief_title>The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)</brief_title>
  <acronym>Trident</acronym>
  <official_title>A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI
      scheduled to undergo cardiac catheterization will be enrolled in the study. This is a phase
      II study intended to gain additional safety and efficacy assessments among two dose levels
      previously studied in a phase I setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI
      scheduled to undergo cardiac catheterization will be enrolled in the study.This is a phase II
      study intended to gain additional safety and efficacy assessments among two dose levels
      previously studied in a phase I setting. In this study, a 20 million total hMSC dose and a
      100 million total hMSC dose will be randomly allocated administered via the Biocardia Helical
      infusion system in a blinded manner.

      The technique of transplanting progenitor cells into a region of damaged myocardium, termed
      cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or
      repair necrotic, scarred, or dysfunctional myocardium. Ideally, graft cells should be readily
      available, easy to culture to ensure adequate quantities for transplantation, and able to
      survive in host myocardium, which is often a hostile environment of limited blood supply and
      immunorejection. Whether effective cellular regenerative strategies require that administered
      cells differentiate into adult cardiomyocytes and couple electromechanically with the
      surrounding myocardium is increasingly controversial and recent evidence suggests that this
      may not be required for effective cardiac repair. Most importantly, transplantation of graft
      cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a
      number of candidate cells have been transplanted in experimental models, including fetal and
      neonatal cardiomyocytes, embryonic stem cell-derived myocytes, tissue engineered contractile
      grafts9, skeletal myoblasts, several cell types derived from adult bone marrow, and cardiac
      precursors residing within the heart itself. There has been substantial clinical development
      in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both
      post-infarction patients and patients with chronic ischemic left ventricular dysfunction and
      heart failure. The effects of bone marrow-derived mesenchymal stem cells (MSCs) have also
      been studied clinically.

      Currently, bone marrow or bone marrow-derived cells represent a highly promising modality for
      cardiac repair. The totality of evidence from trials investigating autologous whole bone
      marrow infusions into patients following myocardial infarction supports the safety of this
      approach. In terms of efficacy, increases in ejection fraction are reported in the majority
      of the trials.

      Chronic ischemic left ventricular dysfunction is a common and problematic condition;
      definitive therapy in the form of heart transplantation is available to only a tiny minority
      of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied
      less than for acute MI, but represents a potentially important alternative for this disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2014</start_date>
  <completion_date type="Actual">September 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Serious Adverse Events (SAE).</measure>
    <time_frame>One month post-catheterization</time_frame>
    <description>Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct Scar Size (ISS)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Determined by delayed contrast enhanced Computed Tomography (CT) Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Reported Tissue Perfusion</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Tissue perfusion measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Oxygen Consumption (VO2)</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Peak VO2 assessed via treadmill determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute Walk Test.</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>A test that measures how far a patient can walk in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.</measure>
    <time_frame>Baseline to 3 months, Baseline to 6 months, Baseline to 12 months</time_frame>
    <description>Changed in NYHA Functional Classification will be evaluated. Worsened: Documented increase in limitation in physical activity. Improved: Documented decrease in limitation in physical activity. Unchanged: No documented change in limitation in physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incidents of Major Adverse Cardiac Events (MACE).</measure>
    <time_frame>1 month, 6 months, 12 months post injection.</time_frame>
    <description>Incidence of the Major Adverse Cardiac Events (MACE) endpoint, defined as the composite incidence of (1) death, (2) hospitalization for worsening heart failure, or (3) non-fatal recurrent MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Event (AE)</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Incidence of Treatment Emergent Adverse Event defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of the study product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure (MLHF) Questionnaire Scores</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Minnesota Living with Heart Failure (MLHF) Questionnaire has a total score from 0 to 105. A higher score indicates that participant's heart failure is preventing them from living their life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic-derived Measures of Left Ventricular Function</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Left ventricular end diastolic wall thickness as determined by echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>As determined by Computed Tomography Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Regional Left Ventricular Wall Thickening</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>As determined by Computed Tomography Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Left Ventricular End Diastolic Wall Thickness</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>As determined by Computed Tomography Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in 1-year LVEF by CT as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in LVEF</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>As assessed via ECHO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Left Ventricular Volume</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via ECHO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Left Ventricular Volume</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Left Ventricular Regional Myocardial Perfusion</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>As measured via myocardial mass by CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Reads.</measure>
    <time_frame>12 months</time_frame>
    <description>The number of participants with abnormal ECG readings via 24 hour ambulatory ECG recordings as assessed per treating physician discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Significant of Abnormal Lab Values.</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical significance of abnormal lab values will be assessed by treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial Troponin I</measure>
    <time_frame>12 hours, 24 hours post cardiac catheterization</time_frame>
    <description>Serial Troponin I values in ng/mL over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal ECHO Reading</measure>
    <time_frame>6 hours post cardiac catheterization</time_frame>
    <description>The number of participants with abnormal reading post-cardiac catheterization. As assessed per treating physician discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Kinase Muscle/Brain (CK-MB)</measure>
    <time_frame>12 hours, 24 hours post cardiac catheterization</time_frame>
    <description>CK-MB values in ng/mL over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Ischemic Left Ventricular Dysfunction</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group 1: 20 million Allogeneic hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 100 million Allogeneic hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic hMSCs</intervention_name>
    <description>Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
    <arm_group_label>Group 1: 20 million Allogeneic hMSCs</arm_group_label>
    <arm_group_label>Group 2: 100 million Allogeneic hMSCs</arm_group_label>
    <other_name>Allogeneic Adult Human Mesenchymal Stem Cells (MSCs)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In order to participate in this study, a patient MUST:

               1. Be ≥ 21 and &lt; 90 years of age.

               2. Provide written informed consent.

               3. Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to
                  myocardial infarction (MI) as defined by previous myocardial infarction
                  documented by an imaging study demonstrating coronary artery disease with
                  corresponding areas of akinesis, dyskinesis, or severe hypokinesis.

               4. Been treated with appropriate maximal medical therapy for heart failure or
                  post-infarction left ventricular dysfunction. For beta-blockade, the patient must
                  have been on a stable dose of a clinically appropriate beta-blocker for 3 months.
                  For angiotensin-converting enzyme inhibition, the patient must have been on a
                  stable dose of a clinically appropriate agent for 1 month.

               5. Be a candidate for cardiac catheterization within 5 to 10 weeks of screening as
                  determined by doctors.

               6. Have an ejection fraction of less than or equal to 50% by gated blood pool scan,
                  two-dimensional echocardiogram, CT, or left ventriculogram within the prior six
                  months and not in the setting of a recent ischemic event.

        Exclusion Criteria:

          -  In order to participate in this study, a patient MUST NOT:

               1. Have a baseline glomerular filtration rate ≤ 35 ml/min/1.73m2.

               2. Have a known, serious radiographic contrast allergy.

               3. Have a Mechanical aortic valve or heart constrictive device.

               4. Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2
                  or less).

               5. Have a documented presence of moderate to severe aortic insufficiency
                  (echocardiographic assessment of aortic insufficiency graded as ≥+2).

               6. Require coronary artery revascularization. Patients who require or undergo
                  revascularization procedures should undergo these procedures a minimum of 3
                  months in advance of treatment in this study. In addition, patients who develop a
                  need for revascularization following enrollment will be submitted for this
                  therapy without delay.

               7. Have evidence of a life-threatening arrhythmia in the absence of a defibrillator
                  (non-sustained ventricular tachycardia ≥ 20 consecutive beats or complete second
                  or third degree heart block in the absence of a functioning pacemaker) or
                  Corrected for heart rate (QTc) interval &gt; 550 ms on screening ECG

               8. Automatic Implantable Cardioverter Defibrillator (AICD) firing in the past 60
                  days prior to enrollment.

               9. Have a hematologic abnormality as evidenced by hematocrit &lt; 25%, white blood cell
                  &lt; 2,500/µl or platelet values &lt; 100,000/µl without another explanation.

              10. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three
                  times the upper limit of normal (ULN).

              11. Have a coagulopathy = (INR &gt; 1.3) not due to a reversible cause (i.e., Coumadin).
                  Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed
                  to have an INR &lt; 1.3. Patients who cannot be withdrawn from Coumadin will be
                  excluded from enrollment

              12. Have known allergies to penicillin or streptomycin.

              13. Hypersensitivity to Dimethyl Sulfoxide (DMSO).

              14. Be an organ transplant recipient.

              15. Have a history of organ or cell transplant rejection

              16. Have a clinical history of malignancy within 5 years (i.e., patients with prior
                  malignancy must be disease free for 5 years), except curatively-treated basal
                  cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.

              17. Have a non-cardiac condition that limits lifespan to &lt; 1 year.

              18. Have a history of drug or alcohol abuse within the past 24 months.

              19. Be on chronic therapy with immunosuppressant medication, such as corticosteroids
                  or TNFα antagonists.

              20. Be serum positive for HIV, hepatitis BsAg or viremic hepatitis C.

              21. Be currently participating (or participated within the previous 30 days) in an
                  investigational therapeutic or device trial.

              22. Be a female who is pregnant, nursing, or of childbearing potential while not
                  practicing effective contraceptive methods. Female patients must undergo a blood
                  or urine pregnancy test at screening and within 36 hours prior to injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua M Hare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ISCI / University of Miami Miller School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISCI / University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine</description>
  </link>
  <reference>
    <citation>Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017 Nov 10;121(11):1279-1290. doi: 10.1161/CIRCRESAHA.117.311827. Epub 2017 Sep 18.</citation>
    <PMID>28923793</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <results_first_submitted>October 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Chief Science Officer, Director of Interdisciplinary Stem Cell Institute</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular</keyword>
  <keyword>Chronic Ischemic Left Ventricular Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02013674/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 20 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 100 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 20 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 100 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="12.2"/>
                    <measurement group_id="B2" value="65.6" spread="9.4"/>
                    <measurement group_id="B3" value="66.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment Ejection Fraction (%)</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="9.9"/>
                    <measurement group_id="B2" value="26.7" spread="6.5"/>
                    <measurement group_id="B3" value="29.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment Glomerular Filtration Rate (mL/Min)</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="24.4"/>
                    <measurement group_id="B2" value="79.2" spread="20.4"/>
                    <measurement group_id="B3" value="74.6" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Serious Adverse Events (SAE).</title>
        <description>Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise).</description>
        <time_frame>One month post-catheterization</time_frame>
        <population>SAEs are collected for 12 months, however, outcome 1 is only for SAEs during the first month.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Serious Adverse Events (SAE).</title>
          <description>Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise).</description>
          <population>SAEs are collected for 12 months, however, outcome 1 is only for SAEs during the first month.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infarct Scar Size (ISS)</title>
        <description>Determined by delayed contrast enhanced Computed Tomography (CT) Scan</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Infarct Scar Size (ISS)</title>
          <description>Determined by delayed contrast enhanced Computed Tomography (CT) Scan</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>Percent of Left Ventricular Mass</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.5" upper_limit="16.6"/>
                    <measurement group_id="O2" value="9.7" lower_limit="6.5" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="4.5" upper_limit="8.6"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.7" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Reported Tissue Perfusion</title>
        <description>Tissue perfusion measured by CT.</description>
        <time_frame>6 months, 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Reported Tissue Perfusion</title>
          <description>Tissue perfusion measured by CT.</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Oxygen Consumption (VO2)</title>
        <description>Peak VO2 assessed via treadmill determination.</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Oxygen Consumption (VO2)</title>
          <description>Peak VO2 assessed via treadmill determination.</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="5.15"/>
                    <measurement group_id="O2" value="16.7" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="5.27"/>
                    <measurement group_id="O2" value="16.5" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="4.94"/>
                    <measurement group_id="O2" value="16.3" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-minute Walk Test.</title>
        <description>A test that measures how far a patient can walk in 6 minutes.</description>
        <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Six-minute Walk Test.</title>
          <description>A test that measures how far a patient can walk in 6 minutes.</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.7" spread="111.62"/>
                    <measurement group_id="O2" value="434.9" spread="120.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.1" spread="109.62"/>
                    <measurement group_id="O2" value="433.5" spread="133.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.4" spread="107.76"/>
                    <measurement group_id="O2" value="453.6" spread="126.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.7" spread="130.19"/>
                    <measurement group_id="O2" value="463.0" spread="143.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.</title>
        <description>Changed in NYHA Functional Classification will be evaluated. Worsened: Documented increase in limitation in physical activity. Improved: Documented decrease in limitation in physical activity. Unchanged: No documented change in limitation in physical activity.</description>
        <time_frame>Baseline to 3 months, Baseline to 6 months, Baseline to 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.</title>
          <description>Changed in NYHA Functional Classification will be evaluated. Worsened: Documented increase in limitation in physical activity. Improved: Documented decrease in limitation in physical activity. Unchanged: No documented change in limitation in physical activity.</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 3 months, Improved</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 3 months, Unchanged</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 3 months, Worsened</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 6 months, Improved</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 6 months, Unchanged</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 6 months, Worsened</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 months, Improved</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 months, Unchanged</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 months, Worsened</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incidents of Major Adverse Cardiac Events (MACE).</title>
        <description>Incidence of the Major Adverse Cardiac Events (MACE) endpoint, defined as the composite incidence of (1) death, (2) hospitalization for worsening heart failure, or (3) non-fatal recurrent MI.</description>
        <time_frame>1 month, 6 months, 12 months post injection.</time_frame>
        <population>Not all participants were able to complete study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incidents of Major Adverse Cardiac Events (MACE).</title>
          <description>Incidence of the Major Adverse Cardiac Events (MACE) endpoint, defined as the composite incidence of (1) death, (2) hospitalization for worsening heart failure, or (3) non-fatal recurrent MI.</description>
          <population>Not all participants were able to complete study.</population>
          <units>Incidents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month from injection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months from injection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months from injection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Event (AE)</title>
        <description>Incidence of Treatment Emergent Adverse Event defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of the study product.</description>
        <time_frame>6 months, 12 months</time_frame>
        <population>Not all participants were able to complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Event (AE)</title>
          <description>Incidence of Treatment Emergent Adverse Event defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of the study product.</description>
          <population>Not all participants were able to complete the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment emergent AE (6 month)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent AE (12 months)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure (MLHF) Questionnaire Scores</title>
        <description>Minnesota Living with Heart Failure (MLHF) Questionnaire has a total score from 0 to 105. A higher score indicates that participant's heart failure is preventing them from living their life.</description>
        <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
        <population>Not all participants were able to complete procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure (MLHF) Questionnaire Scores</title>
          <description>Minnesota Living with Heart Failure (MLHF) Questionnaire has a total score from 0 to 105. A higher score indicates that participant's heart failure is preventing them from living their life.</description>
          <population>Not all participants were able to complete procedure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="21.0" upper_limit="52.0"/>
                    <measurement group_id="O2" value="35.0" lower_limit="6.0" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="10.0" upper_limit="51.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="6.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="16.0" upper_limit="53.0"/>
                    <measurement group_id="O2" value="21.5" lower_limit="9.0" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="4.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="8.0" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic-derived Measures of Left Ventricular Function</title>
        <description>Left ventricular end diastolic wall thickness as determined by echocardiogram.</description>
        <time_frame>6 months, 12 months</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic-derived Measures of Left Ventricular Function</title>
          <description>Left ventricular end diastolic wall thickness as determined by echocardiogram.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>centimeters (cm)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.2" upper_limit="6.3"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.7" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.4" upper_limit="6.9"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.4" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)</title>
        <description>As determined by Computed Tomography Scan</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)</title>
          <description>As determined by Computed Tomography Scan</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Regional Left Ventricular Wall Thickening</title>
        <description>As determined by Computed Tomography Scan</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Regional Left Ventricular Wall Thickening</title>
          <description>As determined by Computed Tomography Scan</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Left Ventricular End Diastolic Wall Thickness</title>
        <description>As determined by Computed Tomography Scan</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Left Ventricular End Diastolic Wall Thickness</title>
          <description>As determined by Computed Tomography Scan</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Change in 1-year LVEF by CT as compared to baseline.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Change in 1-year LVEF by CT as compared to baseline.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>Percentage of ejected blood</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-12.25" upper_limit="32.17"/>
                    <measurement group_id="O2" value="3.00" lower_limit="-8.27" upper_limit="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in LVEF</title>
        <description>As assessed via ECHO</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in LVEF</title>
          <description>As assessed via ECHO</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Left Ventricular Volume</title>
        <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via ECHO</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Left Ventricular Volume</title>
          <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via ECHO</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Left Ventricular Volume</title>
        <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via CT</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Left Ventricular Volume</title>
          <description>Difference in left ventricular end diastolic and end systolic volume will be assessed via CT</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" lower_limit="-15.89" upper_limit="44.76"/>
                    <measurement group_id="O2" value="3.70" lower_limit="-43.85" upper_limit="53.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Left Ventricular Regional Myocardial Perfusion</title>
        <description>As measured via myocardial mass by CT</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Left Ventricular Regional Myocardial Perfusion</title>
          <description>As measured via myocardial mass by CT</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Reads.</title>
        <description>The number of participants with abnormal ECG readings via 24 hour ambulatory ECG recordings as assessed per treating physician discretion.</description>
        <time_frame>12 months</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Reads.</title>
          <description>The number of participants with abnormal ECG readings via 24 hour ambulatory ECG recordings as assessed per treating physician discretion.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline, normal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline, abnormal not clinically significant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline, abnormal, clinically significant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, normal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, abnormal not clinically significant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, abnormal, clinically significant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Significant of Abnormal Lab Values.</title>
        <description>Clinical significance of abnormal lab values will be assessed by treating physician</description>
        <time_frame>12 months</time_frame>
        <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Significant of Abnormal Lab Values.</title>
          <description>Clinical significance of abnormal lab values will be assessed by treating physician</description>
          <population>Data were not available to perform the statistical analyses as described in the protocol for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serial Troponin I</title>
        <description>Serial Troponin I values in ng/mL over time.</description>
        <time_frame>12 hours, 24 hours post cardiac catheterization</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Serial Troponin I</title>
          <description>Serial Troponin I values in ng/mL over time.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12-hours post-catheterization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="0.01" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.01" lower_limit="0.01" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hours post-catheterization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.01" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.01" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal ECHO Reading</title>
        <description>The number of participants with abnormal reading post-cardiac catheterization. As assessed per treating physician discretion.</description>
        <time_frame>6 hours post cardiac catheterization</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECHO Reading</title>
          <description>The number of participants with abnormal reading post-cardiac catheterization. As assessed per treating physician discretion.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Kinase Muscle/Brain (CK-MB)</title>
        <description>CK-MB values in ng/mL over time.</description>
        <time_frame>12 hours, 24 hours post cardiac catheterization</time_frame>
        <population>Not all participants were able to complete the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 100 Million Allogeneic hMSCs</title>
            <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Kinase Muscle/Brain (CK-MB)</title>
          <description>CK-MB values in ng/mL over time.</description>
          <population>Not all participants were able to complete the procedure.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hour post catheterization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" lower_limit="1.50" upper_limit="27.30"/>
                    <measurement group_id="O2" value="2.45" lower_limit="1.20" upper_limit="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post catheterization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="2.40" upper_limit="19.30"/>
                    <measurement group_id="O2" value="4.40" lower_limit="2.40" upper_limit="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected over approximately 1 year period.</time_frame>
      <desc>TE-SAE will only be reported for outcome 1 through 1 month post catheterization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 20 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 100 Million Allogeneic hMSCs</title>
          <description>Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
Allogeneic hMSCs: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Serious adverse events within 6 months of injection for acute coronary syndrome</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterisolerosis</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Serious adverse events within 6 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus Arrest</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye Swelling</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Mass</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Spinal column ste</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stasis dematitis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardioversion</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Impantable defibrillator replacement</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Adverse events within 12 months of injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marietsy pujol / Senior Regulatory Specialist</name_or_title>
      <organization>ISCI / University of Miami Miller School of Medicine</organization>
      <phone>305-243-7273</phone>
      <email>mpujol@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

